英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
hervest查看　hervest　在百度字典中的解释百度英翻中〔查看〕
hervest查看　hervest　在Google字典中的解释Google英翻中〔查看〕
hervest查看　hervest　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • YUVIWEL® (navepegritide)
    A Patient Access Liaison (PAL) can provide you with individualized support and education about achondroplasia and treatment with YUVIWEL Fill out the form below to receive important information about YUVIWEL and connect with a PAL
  • FDA approves drug for pediatric patients with most common . . .
    The effectiveness of Yuviwel was established in a clinical trial that included a randomized, placebo-controlled 52-week double-blind treatment period, followed by a single-arm 52-week open-label
  • FDA approves Ascendis achondroplasia treatment Yuviwe
    The FDA has approved Ascendis' Yuviwel, a once-weekly injection to treat children with achondroplasia, a rare genetic disorder which causes dwarfism
  • FDA Approves Once-Weekly YUVIWEL® (navepegritide) for . . .
    “The approval of once-weekly YUVIWEL is a major step forward in the treatment of children with achondroplasia, giving physicians for the first time the option of prescribing a once-weekly medicine backed by compelling efficacy and excellent tolerability data from three randomized, double-blind, placebo-controlled clinical trials,” said
  • FDA approves Ascendis Pharma’s weekly Yuviwel for paediatric . . .
    The US Food and Drug Administration (FDA) has granted accelerated approval to Ascendis Pharma’s Yuviwel (navepegritide) for the treatment of a rare genetic condition in children that causes dwarfism The once-weekly therapy will be available to children aged two and over with achondroplasia with open growth plates The FDA’s accelerated approval is for the increase of linear growth in
  • FDA Approves Yuviwel for Weekly Treatment of Achondroplasia
    The recent authorization of Yuviwel by the FDA represents a transformative moment for thousands of families navigating the complexities of achondroplasia, effectively dismantling a long-standing market monopoly For the first time,
  • Accelerated Approval of Yuviwel (Navepegritide) for Patients . . .
    This program is designed to encourage development of new drugs and biologics for the prevention or treatment of rare pediatric diseases To learn more about the FDA approval, visit FDA Grants Accelerated Approval to Navepegritide for the Treatment of Patients With Achondroplasia
  • FDA Approves Once-Weekly YUVIWEL for Achondroplasia in . . .
    The FDA has granted accelerated approval for YUVIWEL (navepegritide), the first once-weekly treatment for children with achondroplasia Commercial availabili
  • Yuviwel for Achondroplasia - WebMD
    Yuviwel increased growth rate across ages and genders However, the treatment difference between Yuviwel and placebo was larger in children aged 5 years or older than in those younger than 5 years
  • FDA Approves YUVIWEL, a New Weekly Drug for Achondroplasia
    Experts view YUVIWEL as a significant advancement in achondroplasia treatment, offering a convenient once-weekly option with proven efficacy in improving growth velocity, though long-term benefits require further confirmation





中文字典-英文字典  2005-2009